The industry’s first ALK degrader starts its first human study.
ApexOnco Front Page
Recent articles
MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.
The company reveals its anti-GPRC5D T-cell engager.
First human data on MK-2010 are imminent.
The company’s TRPV1 antagonist looks doomed.
But this comes in second-line breast cancer, a use the group isn’t pursuing.
The company admits defeat with zelenectide.
Pivotal trials and novel combinations have started, but four programmes seem to have been discontinued.
